Cooley Advises Jazz Pharmaceuticals plc on Rule 144A Offering of $575 Million of Exchangeable Senior Notes

Palo Alto – September 25, 2014 – Cooley LLP announced today that it advised Ireland-based Jazz Pharmaceuticals plc (Nasdaq: JAZZ) on its Rule 144A offering of $575 million of exchangeable senior notes due 2021. Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing differentiated products that address unmet medical needs.

The notes were issued by Jazz Investments I Limited, a wholly-owned finance subsidiary of Jazz Pharmaceuticals plc, and are exchangeable for cash, ordinary shares of Jazz Pharmaceuticals plc or a combination of cash and such ordinary shares. The notes are fully and unconditionally guaranteed by Jazz Pharmaceuticals plc.

About Cooley LLP

Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.

Cooley has more than 750 lawyers across 11 offices in the United States and China.

Related Contacts
Susan Cooper Philpot Retired Partner, San Francisco
Mischi a Marca Partner, San Francisco
Chadwick Mills Partner, San Francisco
Francis Wheeler Partner, Colorado
Sale Kwon Associate, Palo Alto
Jason Savich Partner, San Francisco
Matthew Dubofsky Partner, Colorado
Amanda Fant Associate, San Francisco
Sepideh Mousakhani Associate, Palo Alto
Related Practices & Industries

Debt Finance Tax